Sunday, November 8, 2026

USD/EUR Bullish By 2% In The Last 10 Sessions

ViaNews Editorial Team

October 11, 2024

USD/EUR Bullish By 2% In The Last 10 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.13% for the last 10 sessions. At 08:09 EST on Friday, 11 October, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 2.489% up from its 52-week low and 4.052% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.28%, 0.04%, and 0.28%, respectively.

USD/EUR's highest amplitude of average volatility was 0.30% (last week), 0.29% (last month), and 0.28% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • According to FXStreet on Wednesday, 9 October, "This, along with the fact that oscillators on the daily chart have been gaining positive traction, suggests that the path of least resistance for the USD/JPY pair is to the upside. ", "Apart from this, subdued US Dollar (USD) demand fails to assist the USD/JPY pair to capitalize on the overnight bounce from the 147.35-147.30 region and contributes to the range-bound price action during the Asian session on Wednesday. "
  • Usd/jpy price forecast: surges above 149.00 sponsored by elevates US yields. According to FXStreet on Wednesday, 9 October, "If USD/JPY extends its gains above the August 15 high of 149.39, the 150.00 figure will be exposed. ", "The USD/JPY rallied and pushed above 149.00 for the first time since mid-August, sponsored by the jump in US Treasury yields due to their close positive correlation with the pair. "
  • According to FXStreet on Thursday, 10 October, "This, in turn, should help limit the downside for the USD/JPY pair near the 148.00 round figure. ", "Moreover, oscillators on the daily chart have been gaining positive traction and are away from being in the overbought territory, suggesting that the path of least resistance for the USD/JPY pair is to the upside. "
  • Usd/jpy can remain sensitive to US rates – DBS. According to FXStreet on Thursday, 10 October, "With speculative positioning still not deeply short, intervention does not appear to be an imminent risk, and USD/JPY could remain sensitive to US rates for now."
  • According to FXStreet on Friday, 11 October, "The Japanese Yen (JPY) struggles to attract any meaningful buyers during the Asian session on Friday, with the USD/JPY pair holding just below its highest level since early August touched the previous day. ", "Moreover, oscillators on the daily chart have been gaining positive traction and are far from being in the overbought territory, suggesting that the path of least resistance for the USD/JPY pair is to the upside. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com